I AM ALS statement on BrainStorm’s withdrawal of BLA for NurOwn
If you have not seen it yet, BrainStorm issued a press release early this morning: https://ir.brainstorm-cell.com/2023-10-18-BrainStorm-Cell-Therapeutics-to-Meet-with-US-FDA-to-Discuss-Development-Plan-for-NurOwn-as-a-Treatment-of-ALS
We are disappointed to learn that BrainStorm withdrew its FDA Biologics License Application for NurOwn. This means that December 8, 2023 is no longer the designated PDUFA date. Our hearts go out to the people living with ALS who will now have further delayed access to NurOwn. In reality, some people won’t see NurOwn’s approval. I AM ALS’s community support team has support groups to help you during this difficult time.
We are disappointed that we learned this news only a few hours before their meeting. The ALS community deserves better than this. We also knew BrainStorm’s initial trial design was not ideal. It received a 1/5 stars on the Patient-centric Clinical Trial Design (PaCTD) Rating System. We look forward to working with BrainStorm, the FDA, and people living with ALS to ensure their next study is transparent, fast, and has strong confirmatory science to receive a 5/5 on the PaCTD Rating System. All things the initial study lacked.
We will find cures for ALS. The only question is when. That answer depends on you.
Stay informed on I AM ALS’ progress and what you can do to help us make hope real.
Hummingbird Fund and I AM ALS partner to accelerate therapy approvals and access
We are thrilled to announce a new collaboration between I AM ALS and The Hummingbird Fund, a milestone towards achieving our shared mission of ending ALS through revolutionary policy advocacy.
NurOwn AdComm: What happened? What’s next?
There have been a lot of conversations about NurOwn’s Cellular, Tissue, and Gene Therapies Advisory Committee (AdComm) meeting that occurred on September 27, 2023, the subsequent Biologics License Applications (BLA) removal, and its perceived irregularities.